Clinical trials: Covid19 Vaccine
Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization
Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine
COVID-19 is a novel coronavirus infection caused by respiratory droplets and contact transmission. With the spread of the epidemic, it has become a serious threat to global public health.
- Trial name
- NCT05373030
- Testing
- Recombinant adenovirus type-5-vectored COVID-19 vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
COVID-19 Immunization, Influenza Immunization
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States.
- Trial name
- NCT06695130
- Testing
- RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1)
- Where
- 12 sites in United States
- Volunteers
- 980 people, healthy volunteers welcome
- Sponsor
- Sanofi
COVID-19
Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults
This is a multicenter, observer-blind, randomized, controlled phase 3 study to evaluate the immunogenicity, reactogenicity, and safety of an investigational self-amplifying RNA COVID-19 vaccine (ARCT-2303) administered…
- Trial name
- NCT06279871
- Testing
- ARCT-2303, Influenza vaccine, Influenza vaccine, adjuvanted
- Where
- 29 sites in Australia, Costa Rica and 2 more
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
SARS-CoV-2 Virus Infection
Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects
A multicenter, 3-arm randomized dose finding study in the UK to evaluate safety, tolerability and immunogenicity of a vaccine candidate against Covid-19.
- Trial name
- NCT04671017
- Testing
- VLA2001
- Where
- 4 sites in United Kingdom
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Covid19
COVID-19 3rd Dose Vaccine in Transplant Patients
The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.
- Trial name
- NCT05047640
- Testing
- BNT162b2 vaccine, JNJ-78436735 Vaccine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Giselle Guerra
Kidney Failure, Chronic, Covid19
Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy
Chronically dialyzed patients and kidney transplant recipients have been identified as particularly vulnerable to SARS-CoV-2 infection due to unavoidable exposure.
- Conditions
- Kidney Failure, Chronic, Covid19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- COViNEPH-1 (NCT04905862)
- Testing
- Immune response, Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events
- Where
- 4 sites in Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Gdansk
SARS-CoV-2
Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults
The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.
- Trial name
- NCT04715997
- Testing
- GX-19N
- Where
- 5 sites in South Korea
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Lung Cancer, Pulmonary Nodule, Solitary
Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
The objective of this study is to assess the inoculation-related symptoms and long-term effects of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting.
- Conditions
- Lung Cancer, Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple, COVID-19 Pneumonia
- Trial name
- CoVac-Lung (NCT04894682)
- Testing
- Vaccine inoculation against SARS-CoV-2
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Rheumatoid Arthritis, Psoriatic Arthritis
COVID-19 VaccinE Response in Rheumatology Patients
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Trial name
- COVER (NCT05080218)
- Testing
- Upadacitinib, Abatacept, Secukinumab
- Where
- 8 sites in United States
- Volunteers
- 841 people
- Sponsor
- Jeffrey Curtis
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19 Pandemic
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18…
- Trial name
- COVID-19 (NCT05238649)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg, Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg, SARS-Cov-2 Vaccine Inactivated
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
Multisite Observational Maternal and Infant Study for COVID-19
This is an observational, non-interventional, prospective cohort study designed to collect clinical information and specimens to evaluate the immune responses from pregnant individuals and postpartum individuals and their infants…
- Trial name
- MOMI-Vax (NCT05031468)
- Testing
- Licensed or EUA SARS-CoV-2 vaccine
- Where
- 10 sites in United States
- Volunteers
- 562 people, healthy volunteers welcome
- Sponsor
- Emory University
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
A Phase 1 study to evaluate safety, tolerability, and immunogenicity of SARS-CoV-2 variant mRNA vaccines which are used to prevent COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT05434585
- Testing
- ABO1009-DP, ABO-CoV.617.2
- Where
- 2 sites in Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia.
- Conditions
- COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease
- Trial name
- NCT06259578
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
COVID-19, Vaccine Reaction
The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)
While both heterologous (mixing) and homologous (matching) vaccine regimens are now considered standard of care, post-vaccination complications and long-term effects of the different vaccination regimens have not been thoroughly…
- Conditions
- COVID-19, Vaccine Reaction, COVID-19 Pandemic
- Trial name
- BOOSTED (NCT05268185)
- Testing
- Moderna Booster Vaccine, Pfizer Booster Vaccine
- Where
- United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Vaccine Hesitancy
The Effect of Newspaper Reporting on COVID-19 Vaccine Hesitancy: a Randomised Controlled Trial
COVID-19 vaccine hesitancy can be observed at different rates in different countries. 1,068 people were surveyed in France and Italy to inquire about individual potential acceptance, focusing on time preferences, in a risk-return…
- Trial name
- COVANEW (NCT05582564)
- Testing
- abstract vs concrete texts
- Where
- Italy
- Volunteers
- 1,068 people, healthy volunteers welcome
- Sponsor
- University of Bari Aldo Moro
SARS-CoV-2, Safety
The Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (SYS6006) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated With Inactivated SARS-CoV-2 Vaccine
This study plans to enrol 1000 participants 18 years and above, with ≥10% participants ≥60 years old. According to SARS-CoV-2 vaccine vaccination history, they will be evenly divided into 2 groups, Group A and Group B.
- Conditions
- SARS-CoV-2, Safety, Immunotoxicity
- Trial name
- NCT05492643
- Testing
- one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity, Humoral Immunity
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Rheumatic Disease, HIV Infections
COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS
Patients with chronic rheumatic diseases (such as systemic lupus erythematosus [SLE], rheumatoid arthritis [RA], ankylosing spondylitis [AS], juvenile idiopathic arthritis [JIA], poly/dermatomyositis [PM/DM], systemic sclerosis…
- Conditions
- Rheumatic Disease, HIV Infections, AIDS, Safety Issues
- Trial name
- CoronavRheum (NCT04754698)
- Testing
- CoronaVac
- Where
- Brazil
- Volunteers
- 2,196 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.